HBOT for concussion and traumatic brain injury is supported by randomized controlled trials, SPECT neuroimaging studies and the largest published TBI cohort in the field.

Boussi-Gross et al. — RCT in post-concussion syndrome (2013): A randomized controlled trial published in PLOS ONE enrolled 56 patients with mild TBI and persistent post-concussion syndrome (1 to 5 years post-injury) and compared HBOT to a crossover delayed-treatment control. The HBOT group demonstrated statistically significant improvements in cognitive function, quality of life and post-concussive symptom scores. Critically, SPECT neuroimaging confirmed increased brain blood flow and activity in previously hypoperfused regions — providing objective biological evidence of genuine neurological improvement. The imaging changes correlated directly with cognitive gains. [Boussi-Gross R et al. PLoS ONE. 2013;8(11):e79995. PMID: 24224028]

Harch et al. — Veterans with chronic TBI (2012): A prospective trial published in the Journal of Neurotrauma treated 16 Iraq and Afghanistan veterans with persistent post-concussion syndrome and PTSD using HBOT at 1.5 ATA. Significant improvements were documented in post-concussive symptoms, PTSD symptoms, quality of life, cognitive function and suicidal ideation — with suicidal ideation reduced by 83%. SPECT imaging confirmed increased brain perfusion. This study established the potential for HBOT to address both the neurological and psychiatric dimensions of military TBI. [Harch PG et al. J Neurotrauma. 2012;29(1):168–185. PMID: 22026588]

Hadanny et al. — largest TBI cohort (2018): The Sagol Center published the largest cohort study of HBOT in TBI patients in BMJ Open, analyzing outcomes in patients with chronic deficits from injuries ranging from 0.3 to 33 years prior. Significant neurological improvements were documented in memory, attention, executive function, information processing and quality of life, with SPECT neuroimaging confirming the brain changes. The breadth of the cohort — including patients with decades-old injuries — demonstrated that the therapeutic window for HBOT benefit is wider than previously believed. [Hadanny A et al. BMJ Open. 2018;8(9):e023706. PMID: 30185573]

Stem cell mobilization mechanism: Research by Thom et al. demonstrated that HBOT at therapeutic pressures produces an eightfold increase in circulating CD34+ progenitor cells through a nitric oxide-dependent mechanism. These neural progenitor cells home to areas of brain damage and differentiate into neurons and supporting glial cells, providing a biological mechanism for the genuine neurological recovery observed in TBI patients following HBOT. [Thom SR et al. Am J Physiol Heart Circ Physiol. 2006;290(4):H1378–1386. PMID: 16284238]

Neuroinflammation suppression: TBI triggers a prolonged neuroinflammatory cascade — microglial activation, pro-inflammatory cytokine release and reactive oxygen species generation — that expands brain injury well beyond the initial trauma. HBOT suppresses this secondary neuroinflammatory response, reducing microglial activation and cytokine levels in brain tissue, limiting the secondary expansion of injury that accounts for much of the long-term disability after TBI.